Does Amerigroup Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab 60 mg, a RANK ligand inhibitor that slows bone resorption. Given as a subcutaneous injection every six months by a healthcare provider, it carries a list price near $1,400 per dose, making insurer coverage a genuine financial necessity for most patients.

Mechanism and FDA Approval

The FDA approved denosumab 60 mg (Prolia) in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later extended the indication to men with osteoporosis, patients on long-term glucocorticoid therapy, and men with nonmetastatic prostate cancer receiving androgen deprivation therapy [1]. Because the drug targets RANK ligand rather than hydroxyapatite in bone, it carries a different risk profile than bisphosphonates, including a requirement to continue dosing without interruption to avoid rebound bone loss [2].

Clinical Evidence Insurers Evaluate

Amerigroup medical directors reviewing prior authorization requests look at the same trial data that shaped FDA labeling. The FREEDOM trial (N=7,808) demonstrated that denosumab reduced new vertebral fracture risk by 68% over 36 months compared with placebo, and hip fracture risk by 40% [3]. That trial enrolled postmenopausal women with a lumbar spine or total hip T-score between -2.5 and -4.0, which is why Amerigroup coverage criteria often mirror exactly those T-score thresholds. Showing your DXA report with values in that range is one of the strongest pieces of documentation you can submit.

Osteoporosis Prevalence and Why Payers Are Involved

The National Institutes of Health estimates that osteoporosis affects approximately 10 million Americans, with another 44 million having low bone density [4]. Among Medicare-enrolled women over 65, untreated vertebral fractures increase one-year mortality by roughly 20%, which gives insurers a financial incentive to cover effective treatments rather than pay for hospitalizations. That clinical and economic reality does shape formulary decisions, even if it does not guarantee automatic approval for any individual member.

How Amerigroup Plans Are Structured

Amerigroup operates both Medicaid managed care plans in multiple states and Medicare Advantage plans. The coverage rules for Prolia differ significantly between these two product lines.

Amerigroup Medicaid Plans

Amerigroup Medicaid plans follow state Medicaid formulary rules, which vary by state. In states where Amerigroup holds a Medicaid managed care contract (including Georgia, Indiana, Nevada, New Jersey, Tennessee, Texas, Virginia, and others), Prolia typically appears on the formulary as a medical benefit rather than a pharmacy benefit. That distinction matters because:

• Medical benefits are billed under the patient's medical plan through a physician's office or infusion center.
• Pharmacy benefits use the prescription drug card at a pharmacy counter.

When Prolia is a medical benefit, the prescribing provider bills Amerigroup directly using HCPCS code J0897 (denosumab injection, 1 mg; 60 units = 60 mg dose). The patient typically has no out-of-pocket cost on Medicaid if approved, but prior authorization is still required in most Amerigroup Medicaid contracts.

Amerigroup Medicare Advantage Plans

Medicare Advantage plans sold under the Amerigroup brand (now largely consolidated under Anthem/Elevance Health) follow CMS guidelines for Part B injectable drugs. Prolia administered in a physician's office bills under Part B, meaning the plan pays 80% of the Medicare-approved amount after the Part B deductible ($240 in 2024), and the member pays the remaining 20% unless they have supplemental coverage [5]. Some Amerigroup Medicare Advantage plans cap member cost-sharing below the standard 20% coinsurance, so checking your specific plan's Evidence of Coverage document is essential.

Prior authorization requirements under Medicare Advantage plans are governed by CMS rules that took effect in 2023, which set maximum review timelines: 7 calendar days for standard requests and 72 hours for expedited requests [5].

Prior Authorization Criteria for Prolia Through Amerigroup

Most Amerigroup plans use clinical coverage guidelines that align closely with the American College of Rheumatology (ACR) and the National Osteoporosis Foundation (NOF) clinical practice guidelines.

Standard Documentation Required

A complete prior authorization submission for Prolia through Amerigroup generally needs:

• DXA scan results showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, or a T-score between -1.0 and -2.5 with documented high fracture risk on FRAX scoring
• Diagnosis codes (ICD-10: M81.0 for age-related osteoporosis without fracture, or M80-series for pathological fracture)
• Documentation of prior treatment with or contraindication to an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for at least 12 months in most Amerigroup policies, unless a contraindication such as esophageal disease or severe renal impairment is documented)
• Recent lab work confirming adequate calcium and vitamin D levels, and serum creatinine
• Prescriber attestation that the patient can receive the injection in a clinical setting every six months

The NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis (2023 update) recommends pharmacotherapy for postmenopausal women and men over 50 who have a hip or vertebral fracture, a T-score <-2.5, or a FRAX 10-year major osteoporotic fracture probability at or above 20% (or hip fracture probability at or above 3%) [6].

Step Therapy: The Bisphosphonate Hurdle

Amerigroup, like most large managed care organizations, often applies step therapy requiring a documented trial of generic oral bisphosphonates before approving Prolia. Alendronate costs roughly $10-$15 per month generically, versus $1,400 per Prolia dose, so the cost differential drives this policy. You can bypass step therapy if your provider documents any of the following:

• Esophageal stricture or Barrett's esophagus
• Creatinine clearance <35 mL/min (contraindication to bisphosphonate use)
• Documented failure: new fracture or continued bone loss on DXA after 12 months of bisphosphonate therapy
• Prior hypersensitivity or severe musculoskeletal side effects from bisphosphonates
• Inability to remain upright for 30 minutes after dosing

Submitting the Request

Most Amerigroup plans accept prior authorization submissions through:

• The Availity provider portal (availity.com), which Amerigroup uses for most states
• Fax to the plan-specific PA fax number on the back of the member's ID card
• Phone authorization for urgent cases

Turnaround for standard requests is typically 1-3 business days. Under the CMS 2023 prior authorization rules for Medicare Advantage, the maximum allowable review time is 7 calendar days for standard requests [5].

What to Do If Amerigroup Denies Prolia Coverage

Denial is not the end of the process. Most Prolia denials from Amerigroup fall into one of three categories: missing documentation, step therapy not completed, or the request was submitted under the wrong benefit (pharmacy vs. Medical).

Level-One Internal Appeal

File the appeal in writing within the deadline on the denial letter, typically 60-180 days. The appeal letter should include:

• A letter of medical necessity from the prescriber citing specific clinical criteria (T-score value, FRAX score, fracture history)
• Published guideline references, specifically the NOF Clinician's Guide [6] and FREEDOM trial data showing 68% reduction in vertebral fracture risk [3]
• Any additional DXA scans, prior fracture imaging, or lab results not included in the original submission

External Review and State Oversight

If the internal appeal fails, members have the right to an independent external review. For Medicare Advantage members, this goes through a Qualified Independent Contractor (QIC) appointed by CMS. For Medicaid members, the process varies by state but typically involves either an administrative law judge hearing or a state Medicaid agency review.

Expedited Appeals for Clinical Urgency

If a standard timeline would seriously jeopardize health, the treating physician can request an expedited appeal. For Medicare Advantage, the plan must respond within 72 hours under CMS rules [5]. A patient who missed a scheduled Prolia dose and is at imminent fracture risk could qualify for this pathway.

Cost Assistance Programs When Coverage Falls Short

Even with approval, cost-sharing can be a barrier. Several programs reduce or eliminate out-of-pocket costs for Prolia.

Amgen's ARCH Assistance Program

Amgen (Prolia's manufacturer) offers the Amgen Reimbursement Counseling and Hotline (ARCH) program. Commercially insured patients who qualify may pay as little as $0 per dose through the copay card. Medicaid patients are ineligible for manufacturer copay cards under federal anti-kickback rules, but uninsured patients may qualify for free product through the Amgen Safety Net Foundation.

State Pharmaceutical Assistance Programs

Several states run pharmaceutical assistance programs for low-income seniors that can cover the Part B 20% coinsurance on Prolia for Medicare members. States with active programs include New Jersey (PAAD), Pennsylvania (PACE), and New York (EPIC). These operate independently of Amerigroup but can be stacked with it.

Extra Help / Low Income Subsidy

Medicare members who qualify for the Part D Extra Help program (income at or below 150% of the federal poverty level) may receive assistance with Part B cost-sharing through their state Medicaid program in a dual-eligible arrangement, which can reduce or eliminate the 20% coinsurance on Prolia entirely [5].

Clinical Guidelines That Support Coverage Approval

When a prescriber cites specific guidelines in a prior authorization or appeal, approval rates improve. The following guidelines are the most relevant to Prolia coverage determinations.

NOF and AACE Guidance

The National Osteoporosis Foundation's Clinician's Guide recommends denosumab as an appropriate first-line treatment choice for patients with high fracture risk, not just a fallback after bisphosphonate failure [6]. The American Association of Clinical Endocrinologists (AACE) 2020 osteoporosis guidelines similarly list denosumab as a first-line option for patients who cannot tolerate oral bisphosphonates or have renal impairment [7]. Citing both documents in an appeal packet strengthens the medical necessity argument.

Bone Mineral Density Monitoring

The FDA label for Prolia specifies that treatment should not be interrupted because discontinuation leads to rapid bone turnover increase and a risk of multiple vertebral fractures [1]. This means that once a patient begins Prolia, continuity of coverage becomes a patient safety issue, not just a formulary management question. Several published case series have documented vertebral fracture clusters within 12-18 months of denosumab discontinuation [2]. Including a reference to this discontinuation risk in a prior authorization request can shift the framing from elective to medically necessary continuation.

FRAX-Based Decision Making

The World Health Organization developed the FRAX tool to estimate 10-year fracture probability using clinical risk factors with or without BMD [8]. The NOF threshold for treatment is a 10-year major osteoporotic fracture probability at or above 20% or a hip fracture probability at or above 3% [6]. Running a patient's FRAX score and including it in the PA submission is a step many prescribers skip, and it can be the detail that tips a borderline case toward approval.

How Prolia Compares to Covered Alternatives

If Amerigroup denies Prolia, understanding the covered alternatives helps patients and providers choose the next step.

Bisphosphonates

Generic alendronate (Fosamax) and risedronate (Actonel generic) are nearly universally covered on Amerigroup formularies at Tier 1 or Tier 2 with no prior authorization. Alendronate 70 mg weekly reduced vertebral fracture risk by approximately 47% in the Fracture Intervention Trial (N=2,027) over 36 months, compared with 68% for denosumab in FREEDOM [3, 9]. For many patients, bisphosphonates are appropriate. For patients with renal impairment, prior bisphosphonate failure, or a specific contraindication, denosumab may be medically superior.

Zoledronic Acid

Zoledronic acid (Reclast) 5 mg IV once yearly is another option. The HORIZON Key Fracture Trial (N=7,736) showed a 70% relative risk reduction in morphometric vertebral fractures at 36 months [10]. Zoledronic acid is typically covered under the medical benefit similar to Prolia, may require prior authorization, but often faces less restrictive step therapy requirements than denosumab.

Romosozumab and Teriparatide

Romosozumab (Evenity) and teriparatide (Forteo) are anabolic agents with higher list prices and stricter Amerigroup coverage criteria, generally reserved for patients with very severe osteoporosis (T-score <-3.5 or multiple fragility fractures). They are not standard alternatives if the goal is simply to avoid Prolia step therapy.

Practical Steps: A Provider Checklist Before Submitting

Completing each item before submitting reduces the chance of a request being returned for additional information.

1. Confirm the member's Amerigroup plan type (Medicaid vs. Medicare Advantage) and the correct benefit bucket (medical vs. Pharmacy).
2. Pull the most recent DXA report, confirming T-score values at the lumbar spine and hip.
3. Run and print a FRAX calculation using the WHO tool at sheffield.ac.uk/FRAX.
4. Document all prior bisphosphonate trials with dates, doses, duration, and reason for stopping (or contraindication).
5. Include serum calcium, 25-OH vitamin D, and creatinine from the past 90 days.
6. Use Amerigroup's specific prior authorization form for injectable biologics, not the generic drug PA form, because the criteria fields differ.
7. Submit via Availity or fax and retain a confirmation number or fax confirmation page.
8. Set a calendar reminder at day 3 (standard) or hour 72 (expedited) to follow up if no decision is received.

The FDA-approved prescribing information for Prolia specifies dosing as 60 mg every 6 months with adequate calcium (at least 1,000 mg daily) and vitamin D (at least 400 IU daily) supplementation, and notes that patients with hypocalcemia must have the condition corrected before starting treatment [1]. Including confirmation that these supplementation requirements will be met can reduce the chance of a clinical-hold response from the plan's pharmacy department.